Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EREG drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EREG (Epiregulin) ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View EREG Products |
| Gene Delivery | EREG Promise-ORF / Lentivirus Full-length ORF for stable cell lines, preserving native conformation for cell-based assays. |
View EREG Products |
| Benchmark Ab | Anti-EREG Recombinant Antibody Recombinant positive control derived from public benchmark sequences. |
View EREG Products |
| Validator | EREG siRNA Set For knockdown verification and functional validation in vitro. |
View EREG Products |
| Related Target A | EGFR Primary functional receptor for EREG. Crucial for downstream signaling studies and selectivity assays. |
View EGFR Products |
| Related Target B | ERBB4 Alternative low-affinity receptor for EREG. Essential for safety and off-target cross-reactivity screening. |
View ERBB4 Products |
| Related Target C | ADAM17 The primary metalloproteinase responsible for EREG shedding and activation. |
View ADAM17 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Evaluation | Human, Mouse, and Cynomolgus ortholog EREG proteins available with >95% purity verified by SDS-PAGE. |
| EGFR Family Subfamily Counter Screening | Homolog panel proteins (EGF, AREG, HB-EGF) strictly verified by mass spectrometry to guarantee zero cross-contamination. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included to establish assay baselines. |
| False Positives in Cleavage Assays | Sequence-verified pro-EREG and cleaved mature EREG proteins are available for precise shedding assay design. |
Live EREG R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EREG therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and bispecific constructs. EREG (Epiregulin) is a critical ligand of the EGFR family, often overexpressed in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma. As first-generation EGFR-targeted therapies face resistance challenges, the next wave of R&D is targeting EREG directly to bypass resistance or selectively deliver cytotoxic payloads to EREG-overexpressing tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Oncology-focused Biotechs | Colorectal Cancer, NSCLC | Internalization Assay (Need high-purity ECD-Fc and stable Lentivirus cell lines) |
| Bispecific Antibodies (e.g., EREG x EGFR) | Biopharma Innovators | Head & Neck Cancer, Refractory CRC | Dual-binding Validation (Need highly stable EGFR and EREG recombinant proteins) |
| Shedding Inhibitors (ADAM17 blockers) | Small Molecule / mAb Developers | Inflammatory Diseases, Fibrosis | Cleavage Inhibition Assay (Need sequence-verified pro-EREG precursor proteins) |